3563 Nanomedicine (Lond.) (2015) 10(24), 3563–3577 ISSN 1743-5889
part of
Research Article
10.2217/nnm.15.173 © 2015 Future Medicine Ltd
Aim: The present study was focused to evaluate the anticonvulsant effects of phenytoin
(PHT) loaded in the silica core of iron oxide nanoparticles (NPs) in an animal model with
pharmacoresistant seizures. Materials & methods: PHT-loaded NPs were synthesized
and characterized. The anticonvulsant effects of PHT-loaded NPs were investigated
in rats with pharmacoresistant seizures associated with brain P-glycoprotein (P-gp)
overexpression. Results & conclusion: In P-gp-overexpressing rats, administration
of PHT-loaded NPs resulted in reduced prevalence of clonus (40% p < 0.05) and
tonic–clonic seizures (20%; p < 0.02). These effects were not evident when animals
were treated with PHT not loaded in the NPs. The results obtained support the notion
that NPs can be used as drugs carriers to the brain with pharmacoresistant seizures.
Keywords:blood–brainbarrier•nanoparticles•neuronalexcitability•P-glycoprotein
•pharmacorresistance•phenytoin
Background
The International League Against Epilepsy
defined pharmacoresistant epilepsy as the
‘failure of adequate trials of two tolerated
and appropriately chosen and used antiepi-
leptic drugs (AEDs) schedules (whether as
monotherapies or in combination) to achieve
sustained seizure freedom’ [1] . Approximately
a third of the patients with epilepsy are diag-
nosed as drug resistant [2] . Psychiatric, psy-
chological, emotional, economic and social
impairments are some of the repercussions of
pharmacoresistant epilepsy, in addition to a
greater risk of sudden unexpected death and
suicide [3–5] .
Different therapeutic strategies have
been developed to manage pharmacoresis-
tant epilepsy. For example, epilepsy surgery
and neuromodulation occasionally result in
total remission of seizures [6–9] . Neverthe-
less, these procedures have been associated
with adverse effects such as hemorrhage and
infections [10–13] . Moreover, these are expen-
sive procedures, and not all patients fulfill
the criteria to be treated with any of these
therapeutic strategies [14] .
Pharmacoresistant epilepsy has been pro-
posed to result from an increased expression
of drug transporters, such as P-glicoprotein
(P-gp), at the luminal side of the blood–
brain barrier (BBB) [15,16] . This augmented
expression of P-gp limits the penetration of
AEDs into the brain [17–20] , an effect that can
be avoided with the administration of P-gp
blockers [21,22] . Although P-gp inhibitors
might be useful for overcoming drug refrac-
toriness, the low specificity of these inhibitors
and/or their prolonged use could affect the
pharmacokinetics of other drugs, and may
exert pharmacodynamic adverse effects and
toxicity [23,24] .
Nanoparticles (NPs) have been receiving
significant attention for their therapeutic and
diagnostic applications. Some of the charac-
teristics that make them attractive are their
small size, high stability, ability to overcome
organ barriers such as BBB and their bio-
compatibility [25–27] . NPs have been used as
drug carriers for AEDs and anticonvulsant
drugs in animal models of seizures [28–34] .
Nevertheless, at present there are no studies
that determine the effects of AEDs trans-
Phenytoin carried by silica core iron oxide
nanoparticles reduces the expression of
pharmacoresistant seizures in rats
Argelia Rosillo-de la Torre
1
,
Lizbeth Zurita-Olvera
2
,
Sandra Orozco-Suárez
3
,
Perla E Garcia Casillas
4
,
Hermelinda Salgado-Ceballos
3
,
Gabriel Luna-Bárcenas*
,2
& Luisa Rocha**
,1
1
DepartmentofPharmacobiology,Center
ofResearch&AdvancedStudies,Calz.
delosTenoriosNo.235.Col.Granjas
Coapa,14330,Tlalpan,DFMexico
2
Polymer&BiopolymerResearchGroup,
CenterofResearch&AdvancedStudies,
QuerétaroUnit,LibramientoNorponiente
#2000,Fracc.RealdeJuriquilla,76230,
Queretaro,Mexico
3
UnitforMedicalResearchin
NeurologicalDiseases,National
MedicalCenter,Av.Cuauhtémoc330.
Col.Doctores,06720,Cuauhtémoc,
DFMexico
4
InstituteofEngineer&Technology,
AutonomusUniversityofJuarezCity,
Av.delCharrono.450Nte.Col.Partido
Romero,32310,JuarezCity,Chihuahua,
Mexico
*Authorforcorrespondence:
gluna@qro.cinvestav.mx
**Authorforcorrespondence:
lrocha@cinvestav.mx
For reprint orders, please contact: reprints@futuremedicine.com